BTK-Inhibitor Development: A Researcher's Perspective
Healthcare Unfiltered
00:00
I Think the Competitive Landscape Prevents Further Development of BTK Inhibitors
In follicular lymphoma, we saw evidence of activity, but I think the level of activity relative to the efficacy of the medication was the balance didn't support further development. We partnered with Gilead later to take a second generation sick inhibitor called Entosplenib. But by that time, the BTK inhibitors were already out in front and PI3 kinase inhibitors were coming along strong at the time as well. The drug did end up getting approved. It's Tavalise and it's approved for ITP, but it's at a lower dose, maybe more favorable for the patients and so forth. And we saw a lot of patients with CLL able to stay on
Transcript
Play full episode
